<DOC>
	<DOCNO>NCT01756131</DOCNO>
	<brief_summary>A single dose escalation study determine safety , tolerability , pharmacokinetic profile intramuscular subcutaneous injection GSK1265744 long act parenteral ( LAP ) healthy subject . This study consist screen visit , single injection , follow-up evaluation minimum 12 week follow injection .</brief_summary>
	<brief_title>A Single Dose Escalation Study Investigate Safety , Tolerability Pharmacokinetics Intramuscular Subcutaneous Long Acting GSK1265744 Healthy Subjects</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 55 year age inclusive , time signing informed consent . Females childbearing potential negative pregnancy test ( serum urine ) screen Day 1 , agree use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception investigational product undetectable . Body weight great equal 50 kilogram ( kg ) men great equal 45 kg woman body mass index ( BMI ) within range 18.531.0 kilogram per meter square ( inclusive ) . Average QTcB QTcF le 450 millisecond ( msec ) ; QTc le 480 msec subject Bundle Branch Block . Capable give write informed consent , include compliance requirement restriction list consent form As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . A positive prestudy Hepatitis B surface antigen , positive Hepatitis C antibody , positive test HIV antibody result within 3 month screen Highrisk behavior Human Immunodeficiency Virus ( HIV ) infection include one follow risk factor within six month enter study ( day 1 ) : Unprotected vaginal anal sex know HIV infect person casual partner , engage sex work money drug , acquire sexually transmit disease , high risk partner currently previous six month . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . If heparin use pharmacokinetics sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . A positive prestudy drug screen . History regular alcohol consumption within 6 month study define : An average weekly intake great 14 drink male great 7 drink female . Unwilling abstain alcohol 48 hour prior admission study site ( Day 1 ) discharge clinic 48 hour prior draw clinical laboratory test ( Day 7 , Day 14 , Week 3 , Week 4 , Week 6 , Week 8 , Week 12 , followup [ necessary ] ) . Where participation study would result donation blood blood product excess 500 milliliter ( mL ) within 56 day period Lactating female . The subject underlying skin disease disorder ( i.e . infection , inflammation , dermatitis , eczema , drug rash , drug allergy , psoriasis , food allergy , urticaria ) . The subject tattoo dermatological condition overlie gluteus and/or abdominal region may interfere interpretation injection site reaction . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , direct bilirubin value 1.5 time upper limit normal ( isolated bilirubin great 1.5 time upper limit normal acceptable bilirubin fractionate direct bilirubin le 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . The subject 's systolic blood pressure outside range 90140 millimeter mercury ( mmHg ) , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100 beat per minute ( bpm ) female subject 45100 bpm male subject . History clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>